Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
No open-market purchases or sales by Actuate Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Actuate Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q4 2024
- Shares held
- 10.4M
- +285.5K (+2.8%) vs. Q4 2024
- Total value
- $70.4M
- −$10.1M (−12.5%) vs. Q4 2024
- New holders
- 9
- 10 more added
- Sold out
- 3
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACTU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 62 | $20.6M |
| Q1 2026 | 61 | $38.0M |
| Q4 2025 | 45 | $80.2M |
| Q3 2025 | 43 | $80.5M |
| Q2 2025 | 38 | $68.5M |
| Q1 2025 | 25 | $70.4M |
| Q4 2024 | 19 | $80.5M |
| Q3 2024 | 10 | $2.85M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Actuate Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 9,893,651 | $67.0M | 84.59% | 00.0% | Unchanged |
| Voss Capital, LLC | 142,381 | $963.9K | 0.07% | +87,135+157.7% | Added |
| Northern Trust Corp | 53,852 | $364.6K | 0.00% | +53,852 | New |
| Susquehanna International Group, LLP | 47,634 | $322.5K | 0.00% | +47,634 | New |
| Geode Capital Management, LLC | 33,489 | $226.7K | 0.00% | +5,596+20.1% | Added |
| Northwestern University | 27,778 | $188.1K | 0.30% | 00.0% | Unchanged |
| Sigma Planning Corp | 23,675 | $160.3K | 0.01% | +7,600+47.3% | Added |
| Goldman Sachs Group Inc | 22,358 | $151.4K | 0.00% | +11,105+98.7% | Added |
| Royal Bank of Canada | 18,538 | $126.0K | 0.00% | +18,236+6,038.4% | Added |
| Vanguard Group Inc | 18,574 | $125.7K | 0.00% | +4,278+29.9% | Added |
| Mercer Global Advisors Inc | 16,344 | $110.6K | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 16,114 | $109.1K | 0.00% | +16,114 | New |
| Chicago Partners Investment Group LLC | 10,365 | $96.4K | 0.00% | +10,365 | New |
| Citadel Advisors LLC | 14,185 | $96.0K | 0.00% | +14,185 | New |
| Millennium Management LLC | 12,185 | $82.5K | 0.00% | +12,185 | New |
| KG&L Capital Management,LLC | 12,000 | $81.2K | 0.03% | 00.0% | Unchanged |
| SFMG, LLC | 11,000 | $74.5K | 0.01% | +11,000 | New |
| Freestone Capital Holdings, LLC | 10,000 | $67.7K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,598 | $51.4K | 0.00% | −147−1.9% | Reduced |
| Northwestern Mutual Wealth Management Co | 3,125 | $21.2K | 0.00% | +3,125 | New |
| Tower Research Capital LLC (TRC) | 2,555 | $17.3K | 0.00% | +2,555 | New |
| UBS Group AG | 1,979 | $13.4K | 0.00% | +45+2.3% | Added |
| Morgan Stanley | 1,538 | $10.4K | 0.00% | +996+183.8% | Added |
| Citigroup Inc | 649 | $4.39K | 0.00% | +647+32,350.0% | Added |
| Bank of America Corp | 25 | $169 | 0.00% | +1+4.2% | Added |
| Omers Administration Corp | 0 | $0 | 0.00% | −10,583−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −10,465−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3−100.0% | Sold out |